Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

Olivier HuillardParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

, MD,

Emilie BoissierParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Benoit BlanchetParis Descartes University, Cochin Hospital, AP-HP, Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Audrey Thomas-SchoemannParis Descartes University, Cochin Hospital, AP-HP, Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France;Paris Descartes University, Paris Pharmaceutical Research Center, UMR 8638 CNRS, Faculty of Pharmacy, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Anatole CessotParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Pascaline Boudou-RouquetteParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Jean-Philippe DurandParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Romain CoriatParis Descartes University, Cochin Hospital, AP-HP, Gastroenterology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Julie GirouxParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Jerome AlexandreParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

Michel VidalParis Descartes University, Cochin Hospital, AP-HP, Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France;Paris Descartes University, Paris Pharmaceutical Research Center, UMR 8638 CNRS, Faculty of Pharmacy, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Francois GoldwasserParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France+33 1 58 41 17 46; +33 1 58 41 17 45; [email protected]

show all

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

Articles from other publishers (12)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

Citations (15)

Read on this site (3)

Articles from other publishers (12)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date